Alyftrek® (vanzacaftor, tezacaftor, and deutivacaftor)
for Cystic Fibrosis

Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor) is a combination therapy for cystic fibrosis (CF) in patients aged 6 and older with at least one F508del or another responsive CFTR mutation. Vanzacaftor and tezacaftor help faulty CFTR proteins reach the cell surface, while deutivacaftor enhances their function, improving chloride transport and reducing CF symptoms.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Cystic Fibrosis - CF